BRCA1epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
BRCA1epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer
Authors
Keywords
-
Journal
Epigenetics
Volume 7, Issue 11, Pages 1225-1229
Publisher
Informa UK Limited
Online
2012-10-16
DOI
10.4161/epi.22561
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer
- (2012) Kelly L. Bolton JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Recent advances in the molecular understanding of glioblastoma
- (2012) Fonnet E. Bleeker et al. JOURNAL OF NEURO-ONCOLOGY
- A DNA Repair Pathway–Focused Score for Prediction of Outcomes in Ovarian Cancer Treated With Platinum-Based Chemotherapy
- (2012) Josephine Kang et al. JNCI-Journal of the National Cancer Institute
- DNA methylation profiling in the clinic: applications and challenges
- (2012) Holger Heyn et al. NATURE REVIEWS GENETICS
- Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
- (2012) Jonathan Ledermann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of BRCA1 and BRCA2 Mutations With Survival, Chemotherapy Sensitivity, and Gene Mutator Phenotype in Patients With Ovarian Cancer
- (2011) Da Yang et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients WithBRCA1orBRCA2Mutations and Recurrent Ovarian Cancer
- (2011) Stan B. Kaye et al. JOURNAL OF CLINICAL ONCOLOGY
- Integrated genomic analyses of ovarian carcinoma
- (2011) D. Bell et al. NATURE
- Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
- (2010) Daniel P. Silver et al. JOURNAL OF CLINICAL ONCOLOGY
- BRCA1 CpG Island Hypermethylation Predicts Sensitivity to Poly(Adenosine Diphosphate)- Ribose Polymerase Inhibitors
- (2010) Jurgen Veeck et al. JOURNAL OF CLINICAL ONCOLOGY
- Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses inBRCACarrier Ovarian Cancer Correlating With Platinum-Free Interval
- (2010) Peter C. Fong et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA2
- (2010) Yvette Drew et al. JNCI-Journal of the National Cancer Institute
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
- (2010) M William Audeh et al. LANCET
- Pathologic Complete Response Rates in Young Women With BRCA1-Positive Breast Cancers After Neoadjuvant Chemotherapy
- (2009) Tomasz Byrski et al. JOURNAL OF CLINICAL ONCOLOGY
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started